GSK
Taking advantage of new kinds of neural network models to accelerate drug discovery
"The Cerebras CS-3 is a critical component that allows GSK to train language models using biological datasets at a scale and size previously unattainable. These foundational models form the basis of many of our AI systems and play a vital role in the discovery of transformational medicines."
Kim Branson
SVP Global Head of AI and ML @ GSK
Kim Branson, SVP Global Head of AI and ML at GSK, discusses AI for drug discovery and the Cerebras partnership
See how GSK is using the Cerebras System
GSK published findings: EBERT models for epigonomic research were 160 times faster on the CS-3 than on a GPU
arxiv
How AI Is Aiming at the Bad Math of Drug Development
Bloomberg
Unconventional collaborations between biopharma and tech are starting to take off
pharmexec
Unconventional collaborations between biopharma and tech are starting to take off
zdnet.com